EditorialEditorial
Screening, Monitoring, and Treating Children With Juvenile Idiopathic Arthritis-Associated Uveitis: Visualizing Better Outcomes
Sheila T. Angeles-Han and Sunil K. Srivastava
The Journal of Rheumatology November 2022, jrheum.221092; DOI: https://doi.org/10.3899/jrheum.221092
Sheila T. Angeles-Han
STAH is supported by the National Institutes of Health (NIH) National Eye Institute (award no. R01EY030521). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. SKS is supported by research grants from Regeneron, Eyepoint, Gilead. S.T. Angeles-Han, MD, MSc, Division of Rheumatology, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati, and Division of Ophthalmology, Cincinnati Children's Hospital Medical Center and Department of Ophthalmology, University of Cincinnati; S.K. Srivastava, MD, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA. STAH is lead principal investigator of the American College of Rheumatology/ Arthritis Foundation guideline. SKS receives consulting fees for Bausch, Allergan, Novartis, jCyte, Eyepoint, Zeiss, and Adverum. Address correspondence to Dr. S.T. Angeles-Han, Associate Professor of Pediatrics, Assistant Professor of Ophthalmology, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, 3333 Burnett Avenue, Cincinnati, OH 45229, USA; Department of Pediatrics, University of Cincinnati, Cincinnati, OH 45229, USA. Email: sheila.angeles-han@cchmc.org.
Sunil K. Srivastava
STAH is supported by the National Institutes of Health (NIH) National Eye Institute (award no. R01EY030521). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. SKS is supported by research grants from Regeneron, Eyepoint, Gilead. S.T. Angeles-Han, MD, MSc, Division of Rheumatology, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati, and Division of Ophthalmology, Cincinnati Children's Hospital Medical Center and Department of Ophthalmology, University of Cincinnati; S.K. Srivastava, MD, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA. STAH is lead principal investigator of the American College of Rheumatology/ Arthritis Foundation guideline. SKS receives consulting fees for Bausch, Allergan, Novartis, jCyte, Eyepoint, Zeiss, and Adverum. Address correspondence to Dr. S.T. Angeles-Han, Associate Professor of Pediatrics, Assistant Professor of Ophthalmology, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, 3333 Burnett Avenue, Cincinnati, OH 45229, USA; Department of Pediatrics, University of Cincinnati, Cincinnati, OH 45229, USA. Email: sheila.angeles-han@cchmc.org.
Abstract
Noninfectious ocular inflammatory disease, or uveitis, is a common and devastating complication of juvenile idiopathic arthritis (JIA). As many as 20% of children with JIA develop JIA-associated uveitis (JIA-U), and 50% experience ocular complications that can lead to damage.1,2
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Screening, Monitoring, and Treating Children With Juvenile Idiopathic Arthritis-Associated Uveitis: Visualizing Better Outcomes
Sheila T. Angeles-Han, Sunil K. Srivastava
The Journal of Rheumatology Nov 2022, jrheum.221092; DOI: 10.3899/jrheum.221092